Drug intelligence / Profile preview

ALXN1810

Development stage: Preclinical
Lead developer: Alexion Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

ALXN1810, formerly known as SYN-101, is a clinical-stage anti-FcRn monoclonal antibody developed by Syntimmune and subsequently acquired by Alexion Pharmaceuticals. It is designed to treat IgG-mediated autoimmune diseases by targeting the neonatal Fc receptor (FcRn), which plays a crucial role in regulating the levels of circulating IgG antibodies. By blocking FcRn, ALXN1810 aims to reduce pathogenic IgG antibodies, thereby addressing the underlying cause of various autoimmune conditions.

Targets

Beyond the preview

Go deeper on ALXN1810.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALXN1810.

Explore the full profile